Immune Alveolar Alterations During Pneumonia-Associated Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome Clinical Trial

— PICARD2  

Official title:

Immune Alveolar Alterations During Pneumonia-Associated Acute Respiratory Distress Syndrome

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03971006
• Other study ID #: APHP 190092
• Status: Not yet recruiting
• Start date: June 1, 2019
• Est. completion date: June 28, 2022

Study information

• Verified date: May 2019
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Nicolas DE PROST, Doctor
• Phone: 01 49 81 23 94
• Email: nicolas.de-prost[@]aphp.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sepsis is a dysregulated host response to severe life-threatening infections, leading to organ failure and death in up to 40% of patients with septic shock. Pulmonary infections are the main cause of community-acquired sepsis and frequently lead to the development of acute respiratory distress syndrome(ARDS). Features of immunosuppression, including diminished cell surface monocyte human leukocyte antigen DR (mHLA-DR) expression, are strongly associated with hospital mortality. Such decrease in HLA-DR expression on antigen-presenting cells has been associated with impairment of microbial antigens to Tcells. Septic patients also show elevated expression of inhibitory receptors associated with cell exhaustion.. Yet, biochemical, flow cytometric and immunohistochemical findings consistent with immunosuppression have been observed in lungs and spleen of patients died of sepsis and multiple organ failure, demonstrating the relevance of studying these defects directly in organ tissues. A novel approach aimed to characterize the role and prognostic value of alveolar biomarkers measured directly in the injured lungs is warranted and supported by: -disappointing results of previous clinical trials attempting to restore the level of biomarkers measured on circulating cells; -evidences of regional immunosuppression in lungs of ARDS patients; -lung is the main site of hospital-acquired infections with a prevalence of ventilator-associated pneumonia in 30% over the course of Intensive Care Unit(ICU) stay in ARDS patients.

Investigators speculate that biomarkers measured on alveolar leukocytes (AL) surface, are important predictors of outcome and potential therapeutic targets in ICU patients with pneumonia-associated ARDS.

Investigators aim to explore whether biomarkers measured directly on AL from patients with pneumonia-associated ARDS are associated to regional pulmonary immunosuppression using leukocyte functional tests; and predictors of outcomes.

Bronchoalveolar lavage fluid(BALF) and blood samples will be collected in ARDS patients. Leukocyte populations and cell membrane biomarkers will be quantified using flow cytometry. Leukocyte functional tests will be performed ex vivo on leukocytes collected from BALF and blood samples. Pharmacological interventions will be performed ex vivo.

This project aims to identify biomarkers associated with outcomes and potential therapeutic targets.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 110
• Est. completion date: June 28, 2022
• Est. primary completion date: June 4, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Affiliated to a social security system

• Patient informed and have given his non opposition verbally (trustworthy or a family member non opposition is required if the patient is unable to give his non opposition)

Groupe 1 :

• Patient with ARDS secondary to pneumonia defined by following criteria: Intubation and mechanical ventilation for less than 48 hours Lung infection evolving since less than 7 days Bilateral pulmonary radiological opacities compatible with edema pulmonary lesion PaO2 / FiO2 ratio = 300 mmHg with a positive expiratory pressure level = 5 cmH2O

• Absence of immunosuppression (No HIV infection, bone marrow or solid organ transplantation, post-chemotherapy aplasia, immunosuppressive therapy or corticosteroid therapy (>200 mg / day of hydrocortisone or equivalent in the 4 weeks prior to inclusion))

Group 2 - Patient with ARDS secondary to pneumonia defined by following criteria:

Intubation and mechanical ventilation for less than 48 hours Lung infection evolving since less than 7 days Bilateral pulmonary radiological opacities compatible with edema pulmonary lesion PaO2 / FiO2 ratio = 300 mmHg with a positive expiratory pressure level = 5 cmH2O

• Previously known immunosuppression (patient with HIV, solid tumor, solid organ transplantation or under corticosteroids therapy since at least 4 weeks before inclusion)

Group 3

• LBA indicated in usual care

• Absence of ARDS

• Absence of evolutionary infection

• Absence of infiltrative lung disease

• Absence of immunosuppression (No HIV infection, bone marrow or solid organ transplantation, post-chemotherapy aplasia, immunosuppressive therapy, corticosteroid therapy (> 200 mg / day of hydrocortisone or equivalent in the 4 weeks prior to inclusion))

Exclusion Criteria:

• Chronic respiratory insufficiency treated by long-term oxygen therapy and / or long-term respiratory assistance

• Child-Pugh C cirrhosis

• Pulmonary fibrosis

• Active lymphoid and myeloid malignant hemopathies

• Neutropenia (neutrophils <1500 / mm3)

• Patient moribund the day of inclusion or having an IGS II score greater than 90

• Irreversible neurological pathology: cerebral involvement, encephalic death

• Decision to limit active therapies

• Deep hypoxemia (PaO2 / FiO2 <75 mmHg)

• Patient protected by law

• Pregnant or lactating woman

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Pneumonia
• Respiratory Distress Syndrome, Adult
• Respiratory Distress Syndrome, Newborn
• Syndrome

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HLA-DR expression level of alveolar monocytes at the early phase of infectious Acute Respiratory Distress Syndrome (ARDS)	Measurement by flow cytometry phagocytosis and TNF-a synthesis of alveolar monocytes in immunocompetent patients, compared to immunocompromised patients	at day 1 to day 3
Secondary	Impact of the level of expression of PD-1 by alveolar CD8 + lymphocytes on their function during septic ARDS in immunocompetent and immunocompromised patients.	Level of expression of PD-1 by alveolar CD8+ lymphocytes	at day 1 to day 3
Secondary	Comparaison of the level of HLA-DR expression of alveolar monocytes between immunocompetent and immunosuppressed patients being managed for septic ARDS.	Level of HLA-DR expression of alveolar monocytes	at day 1 to day 3
Secondary	Link between the alveolar monocyte HLA-DR expression level and the prognosis of immunocompetent and immunosuppressed patients being managed for septic ARDS.	Number of days without complication	day 28
Secondary	Determine wether alveolar biomarkers (HLA-DR and PD-1) are potential candidates for immunomodulation	To determine if the level of expression of HLA-DR and PD-1 can be modulated by pharmacological intervention	at day 1 to day 3